Literature DB >> 6532805

Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs.

A Rakhit, T W Guentert, N H Holford, J Verhoeven, S Riegelman.   

Abstract

Quinidine and one of its major metabolites, quinidine-N-oxide, were given by separate i.v. infusions to each of three beagle dogs. Plasma and urine samples were analysed for pharmacokinetic comparison of the drug and its metabolite. Quinidine apparently distributed into two major compartments, while the N-oxide distributed into three compartments. The compartment-independent pharmacokinetic parameters (mean +/- SD) were for quinidine Vdss 4.78 +/- 1.11 l/kg, clearance 0.074 +/- 0.047 l/min, terminal half-life 720 +/- 343 min and for quinidine-N-oxide Vdss 1.03 +/- 0.21 l/kg, clearance 0.065 +/- 0.012 l/min, terminal half-life 316 +/- 69 min. Only 29% of quinidine was recovered in the urine as unchanged drug while 77% of the N-oxide was excreted unchanged via the kidney. Non-linear renal elimination of the N-oxide was observed in two out of three dogs with a Michaelis-Menten constant, KM of about 7 micrograms/ml (21 microM). Prolongation of the QT-interval in the ECG response was used for comparing pharmacodynamic effects. Quinidine was about three to four fold more active than the N-oxide at similar plasma concentrations. Quinidine-N-oxide concentrations in plasma after quinidine administration were very low and would not contribute significantly to the quinidine effect.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6532805     DOI: 10.1007/BF03189683

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  Renal tubular secretion and reabsorption of organic bases in the dog.

Authors:  J TORRETTI; I M WEINER; G H MUDGE
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

2.  The PROPHET system and resource sharing.

Authors:  W F Raub
Journal:  Fed Proc       Date:  1974-12

3.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

4.  Quinidine excretion in aciduria and alkaluria.

Authors:  R E Gerhardt; R F Knouss; P T Thyrum; R J Luchi; J J Morris
Journal:  Ann Intern Med       Date:  1969-11       Impact factor: 25.391

5.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration.

Authors:  D Perrier; M Mayersohn
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

6.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

7.  An integrated approach to measurements of quinidine and metabolites in biological fluids.

Authors:  T W Guentert; A Rakhit; R A Upton; S Riegelman
Journal:  J Chromatogr       Date:  1980-10-10

8.  Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function.

Authors:  D E Drayer; D T Lowenthal; K M Restivo; A Schwartz; C E Cook; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

9.  Isolation, characterisation and synthesis of a new quinidine metabolite.

Authors:  T W Guentert; J J Daly; S Riegelman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

10.  Pharmacokinetics of quinidine and three of its metabolites in man.

Authors:  A Rakhit; N H Holford; T W Guentert; K Maloney; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1984-02
View more
  2 in total

1.  Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls.

Authors:  F M Gengo; S C Fagan; G Krol; H Bernhard
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

Review 2.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.